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OBJECTIVES We sought to evaluate the effects of mechanical thrombectomy on myocardial reperfusion
during direct angioplasty for acute myocardial infarction (AMI).
BACKGROUND Embolization of thrombus and plaque debris may occur during direct angioplasty for AMI.
This may lead to distal vessel or side branch occlusion and to obstructions in the microvascular
system, resulting in impaired myocardial reperfusion. Mechanical thrombectomy is used to
reduce distal embolization.
METHODS Ninety-two patients with AMI and angiographic evidence of intraluminal thrombus were
randomized to either intracoronary thrombectomy followed by stenting or to a conventional
strategy of stenting. Thrombectomy was performed using the X-Sizer catheter (EndiCOR
Inc., San Clemente, California). Myocardial reperfusion was assessed by myocardial blush and
ST resolution.
RESULTS Postprocedure Thrombolysis in Myocardial Infarction-3 flow was not different between
groups (93.5% vs. 95.7%, p  0.39). Myocardial blush-3 was observed in 71.7% of patients
undergoing thrombectomy and in 36.9% of patients undergoing conventional strategy (p 
0.006). ST-segment resolution 50% occurred more often in patients undergoing throm-
bectomy (82.6% vs. 52.2%, p  0.001). By multivariate analysis, adjunctive thrombectomy
was an independent predictor of blush-3 (odds ratio, 3.27; 95% confidence interval, 1.06 to
10.05; p  0.039).
CONCLUSIONS Intracoronary thrombectomy as adjunct to stenting during direct angioplasty for AMI
improves myocardial reperfusion as assessed by myocardial blush and ST resolution. (J Am
Coll Cardiol 2003;42:1395–402) © 2003 by the American College of Cardiology Foundation
At present, for most patients with acute myocardial infarc-
tion (AMI), direct percutaneous coronary angioplasty
(PTCA) is the best reperfusion strategy (1). This strategy,
particularly when using coronary stents, has been shown to
increase patency of the infarct-related artery (IRA) (2,3).
However, a discrepancy between vessel patency and rescue
of jeopardized myocardium after pharmacologic or interven-
tional treatment of AMI has been documented in up to
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one-third of patients (4–8). This condition may be multi-
factorial and reflects damage to microvascular integrity,
established both during ischemia and at the time of reper-
fusion. Possible related factors include damage to endothe-
lial cells; tissue edema (9,10); release of vasoconstrictive and
inflammatory mediators; intravascular plugging of leuko-
cytes (11,12), platelets, and fibrin aggregates (13). More-
over, embolization of plaque and thrombus debris, either
spontaneous or induced by percutaneous intervention, may
lead to obstruction in distal coronary arterioles, limiting the
efficacy and the extent of myocardial reperfusion (14). New
mechanical devices to remove thrombus or to prevent
embolization of thrombus and plaque during percutaneous
coronary interventions have become available (15–17), but
little is known regarding the effects on myocardial reperfu-
sion during direct angioplasty (18).
The present randomized study was designed to evaluate
the effects of mechanical thrombus removal on myocardial
reperfusion in patients undergoing direct angioplasty for
AMI.
METHODS
Patient population. Between August 2000 and October
2001, 92 patients undergoing direct PTCA within 12 h
from onset of AMI were enrolled in the study.
Inclusion criteria were continuous chest pain for at least
30 min and within 12 h of onset of pain, and ST-segment
elevation1 mm (0.1 mV) in two or more contiguous leads
on the 12-lead electrocardiogram (ECG) (ST-segment
depression in the right precordial leads V1 to V4 was
considered a sign of transmural ischemia of the posterior
myocardial wall), angiographic evidence of intraluminal
thrombus in the IRA, Thrombolysis In Myocardial Infarc-
tion (TIMI) flow2, and/or70% diameter stenosis (DS).
Exclusion criteria were presence of left bundle-branch
block or pacemaker-induced rhythm at admission ECG, left
main stem lesions, IRA diameter 2.5 mm.
Patients older than 75 years and patients in cardiogenic
shock were not excluded from the study. After providing
informed consent, patients fulfilling the inclusion criteria
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were 1:1 randomly assigned to a strategy of intracoronary
thrombectomy followed by stenting, or to a conventional
strategy of stenting alone.
Procedure and device description. Thrombectomy was
performed using the X-Sizer catheter system (ev-3, White
Bear Lake, Minnesota). The device is a two-lumen over-
the-wire system (available diameters 1.5, 2.0, and 2.3 mm)
with a helical shape cutter at its distal tip. The cutter rotates
at 2,100 rpm driven by a hand-held battery motor unit. One
catheter lumen is connected to a 250-ml vacuum bottle, and
aspirated debris is collected in an in-line filter. Two or three
passages across the lesion from proximal to distal were
performed by slowly advancing the activated catheter. Sub-
sequently, additional balloon angioplasty and/or coronary
stenting was performed (Fig. 1). Before the intervention all
patients received aspirin. Heparin (70 U/kg) was given to
maintain the activated clotting time 250 s. Glycoprotein
IIb/IIIa inhibitors were used according to the judgment of
the operator.
Angiographic analysis. The coronary angiograms were
performed using digital technique (Integris 3000, Philips
Medical Systems, Best, the Netherlands). Intracoronary
thrombus was angiographically identified and scored in five
degrees as previously described by Gibson et al. (19).
Patients were enrolled if TIMI thrombus score was 2.
Thrombus score, TIMI flow grade (20), and myocardial
blush grade (MBG) as described by van’t Hof et al. (8) after
guidewire positioning, after thrombectomy, and at the end
of the procedure were determined off-line by two experi-
enced operators blinded to clinical data. Quantitative coro-
nary analysis was performed using the Coronary Quantifi-
cation Package (Philips Medical Systems, Eindhoven, The
Netherlands). Technical success of thrombectomy was de-
fined as the ability of the device to cross the target lesion and
to increase TIMI flow by 1 and/or to reduce TIMI
thrombus score by 1. Procedural success of the interven-
tion was defined by the achievement of TIMI 3 flow grade
and a residual stenosis 20%.
Electrocardiographic analysis. In each patient a 12-lead
ECG was recorded at admission and 60 min after the
procedure. The sum of ST-segment elevation was assessed
at 20 ms from J-point in the leads V1 to V6, I, and aVL for
anterior infarction and in the leads II, III, aVF, V5, V6 for
nonanterior infarction; in the latter the ST-segment depres-
sion in leads V1 to V4 was also analyzed, as a sign of
transmural ischemia of the posterior wall. The two ECGs
were compared, and the ST-segment elevation was classified
as normalized if there was no residual ST-segment elevation
after the procedure, improved if a regression 50% was
observed, unchanged if the ST-segment elevation sum
appeared unchanged, worsened or regressed 50% (21).
Echocardiogaphic analysis. All patients underwent two-
dimensional-transthoracic echocardiographic examination
(Sonos 5500 Hewlett-Packard, Andover, Massachusetts) at
admission, at discharge, and at 30-day follow-up. Left
ventricular ejection fraction was calculated using the area-
length method in the apical four-chamber view and the
apical two-chamber view (22). All measures were given as
mean value of two views.
Enzymatic infarct size. Infarct size was estimated by
measurement of enzyme activity by using total creatine
kinase (CK) and band fraction MB as reference enzymes.
The enzymatic activity was reported as unit of activity per
liter, and was assessed every 6 h in the first 48 h after
admission, and then twice daily up to discharge. Peak value
release from eight serial measurements up to 48 h after
admission was reported.
Histopathological analysis. In 24 of 46 (52.2%) patients
undergoing thrombectomy, histopathologic analysis was
performed on debris collected in the filter by light micros-
copy after staining with hematoxylin-eosin and Azan-Mallory.
Study end points. The primary end point of this study was
the occurrence of postprocedural MBG-3. Secondary end
points included ST-segment regression 50%, enzymatic
infarct size, left ventricular ejection fraction at discharge,
and in-hospital occurrence of heart failure. In-hospital and
30-day occurrence of adverse events including death, non-
fatal reinfarction, stroke, and major bleedings were also
collected.
Follow-up. At 30 days after the procedure, the patients
underwent clinical and echocardiographic evaluation.
Abbreviations and Acronyms
AMI  acute myocardial infarction
CK  creatine kinase
DS  diameter stenosis
IRA  infarct-related artery
MBG  myocardial blush grade
PTCA  percutaneous transluminal coronary angioplasty
TIMI  Thrombolysis In Myocardial Infarction
Figure 1. Angiographic images of thrombectomy procedure. (A) Occluded
proximal left descending artery (arrow). (B) Intraluminal thrombus (arrow)
evidenced after crossing the lesion with a wire. (C) Result after thrombec-
tomy. (D) Final result after direct stent deployment.
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Statistical analysis. The number of patients included in
the study was based on the estimation of the sample size
needed to identify a significant difference in the primary end
point. In a pilot study on thrombectomy in patients with
acute myocardial infarction, we found a rate of 60% in
postprocedural MBG-3 (23). Assuming that the rate of
MBG-3 is around 30% in patients treated with standard
approach direct PTCA (8,24), we estimated that 45 patients
would be required in each group for the study to have a
power of 80% to detect an absolute difference in the
occurrence of MBG-3 of 30% with a two-sided alpha value
of 0.05. All analyses were performed according to intention-
to-treat principle. Categorical variables are presented as
frequency values and were compared by Fisher exact test and
chi-square. The Fisher exact test was used when the
expected event had a low frequency, particularly when at
least one cell in 2-2 table had a value 5; otherwise the
chi-square test was used. Continuous variables are expressed
as mean  SD, and were compared by Student t test or
analysis of variance (ANOVA) for normally distributed
variables, and by Wilcoxon rank-sum test for not normally
distributed variables. Repeated measures of continuous vari-
ables of each group were analyzed by repeated measures
ANOVA with Bonferroni correction for multiple compar-
isons. Multivariate regression analysis was performed to
identify independent predictors of MBG-3 after the proce-
dure. This model included age 65 years, infarct location,
diabetes, Killip class2, ischemic time, previous myocardial
infarction, blood pressure 100 mm Hg, heart ratio 100
beats/min, multivessel disease, occluded IRA at baseline,
the presence of collaterals, use of glycoprotein IIb/IIIa
inhibitors, and thrombectomy. A p value 0.05 was inter-
preted as statistically significant. Statistical analysis was
performed using SPSS 11.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Ninety-two patients meeting the inclusion criteria were
enrolled. Forty-six patients were randomly assigned to
undergo thrombectomy, and 46 to conventional percutane-
ous coronary interventions. There were no significant dif-
ferences in baseline clinical and angiographic characteristics
between groups (Tables 1 and 2).
Procedural data and angiographic analysis. Procedural
angiographic results are reported in Figure 2 and Table 2.
The postprocedural TIMI flow was similar between patients
undergoing thrombectomy and patients treated convention-
ally (p  0.39). Postprocedural DS, minimal lumen diam-
eter, and reference vessel diameter were not different be-
tween groups. The procedural success, as previously defined,
was reached in 43 of 46 (93.5%) patients undergoing
thrombectomy and in 44 of 46 (95.6%) patients assigned to
conventional treatment (p  0.43). Angiographic no-reflow
and distal embolization tended to occur less commonly in
patients randomized to thrombectomy (Table 2). Side
branch occlusion was similar in both groups, and coronary
perforation was not observed.
The rate of patients treated with stent implantation was
similar in both groups. Likewise, the number of stents per
patient, the mean stented segment length, and the stent/
vessel ratio, as well as the maximum pressure of balloon
inflation was not statistically different between groups. Stent
implantation without balloon predilation was performed
more often in patients undergoing thrombectomy (p 
0.003). The administration of glycoprotein IIb/IIIa inhibi-




(n  46) p Value
Age, yrs 61.3  10.8 63.6  11.7 0.33*
Male gender, % 82.6 71.7 0.32‡
Smokers, %
Current 45.6 34.8 0.39‡
Former 20.5 30.4 0.34‡
Hypertension, % 60.9 65.2 0.38‡
Dyslipidemia, % 50.0 52.1 1.0‡
Diabetes, % 13.0 13.0 1.0‡
Previous MI, % 17.4 6.5 0.19§
Anterior MI, % 39.1 43.5 0.83‡
Time from onset of symptoms to hospital
presentation, min
202.9  204.9 165.7  134.7 0.54†
Time from hospital presentation to
angioplasty, min
35  12 38  15 0.82†
Multivessel disease, % 52.2 41.3 0.46‡
Killip class, mean 1.5  1.0 1.5  0.9 0.83†
Killip class IV, % 8.7 8.7 1.0§
HR  100 beats/min, % 19.6 13.0 0.57‡
BP  100 mm Hg, % 15.2 15.2 1.0‡
Continuous data presented as mean  SD and were compared by Student t test (*) or Wilcoxon rank-sum test (†); categorical
data are presented as frequency values and were compared by chi-square (‡) or Fisher exact test (§).
BP  blood pressure; HR  heart rate; MI  myocardial infarction.
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tors and the use of intraaortic balloon pump were not
different between groups.
Thrombectomy results. In 42 of 46 (91.3%) patients
assigned to thrombectomy, the activated device could be
advanced through the target lesion. The number of passages
across the lesion was 2.6  1.2. In one case (2.2%), it was
not possible to reach the target lesion because of proximal
vessel tortousity, and in three patients (6.5%) the device did
not cross a severe lesion. Technical thrombectomy success as
defined above was achieved in 40 of 46 (86.9%) attempted
lesions. After thrombectomy, TIMI flow grade increased
from 1.46  1.24 to 2.61  0.83 (p  0.0001 vs. baseline),
and further increased to 2.91  0.35 after PTCA or
stenting (p  0.004 vs. thrombectomy). After thrombec-
tomy in 34 of 46 attempted lesions (73.9%), there was no
further angiographic evidence of thrombus; in eight (17.4%)
the thrombus score decreased1 degree, and in four (8.6%)
it appeared unchanged. Among these four patients, in three
the device failed to reach or to cross the lesion. The mean
TIMI thrombus score significantly decreased from 3.5 
1.9 to 1.6  0.9 after aspiration (p  0.04). In 30 cases
(65.2%) there was macroscopic evidence of material col-
lected in the filter. The histopathology analysis of the
aspirated material (n  24) evidenced fibrin and platelet
aggregates, typically seen in thrombus, in 86% of analyzed
samples. Macrophages, amorphous lipids, and cholesterol
clefts, representative of the atheromatous plaque, were
identified in 21% of samples.
Assessment of myocardial reperfusion. In patients under-
going thrombectomy, MBG increased from 0.57  0.83 at
baseline to 2.15  1.12 after thrombectomy (p  0.001).
After stenting, final MBG was 2.50  0.91, not showing
further significant increase (p  0.20). In patients under-
going standard approach, MBG significantly improved
from 0.89  1.01 at baseline to 1.67  1.21 after interven-
tion (p  0.01). In patients treated with thrombectomy,
final mean MBG was significantly higher (p  0.001) and
final MBG-3 was observed more often (p  0.006) (Figs. 2
and 3). Regardless of treatment strategy, the use of glyco-
protein IIb/IIIa inhibitors did not affect the final TIMI
flow, and the final MBG grade (Fig. 4). By multivariate
analysis, thrombectomy was an independent predictor of
postprocedural MBG-3 (odds ratio, 3.27; 95% confidence
interval, 1.06 to 10.05; p  0.02).
Assessing the reperfusion according to ECG criteria,
postprocedural ST-segment elevation regressed 50% in a
significantly higher percentage of patients treated with
thrombectomy (82.6% vs. 52.2%; p  0.001) (Table 3).
Infarct size and left ventricular function. The CK and
CK-MB peak release and left ventricular ejection fraction at
baseline, discharge, and at 30 days were not significantly
different between groups (Table 3). Regardless of treatment




(n  46) p Value
Baseline angiographic data
Patent IRA, % 17.4 19.6 0.84‡
Collaterals, % 21.7 23.9 1.0‡
TIMI flow, mean 1.46  1.24 1.48  1.31 0.93†
RVD, mm 3.28  0.80 3.28  0.42 0.99†
MLD, mm 0.31  0.53 0.21  0.28 0.24†
DS, % 94.1  7.2 94.2  6.9 0.94†
Thrombus score, mean 3.9  1.0 3.8  1.1 0.36†
Final angiographic data
TIMI flow final, mean 2.91  0.35 2.89  0.53 0.82†
RVD final, mm 3.39  0.67 3.31  0.40 0.49†
MLD final, mm 3.20  0.45 3.00  0.79 0.12†
DS final, % 8.0  10.6 9.2  20.1 0.73†
Thrombus score final, mean 0.10  0.2 0.15  0.3 0.10†
Procedural details
Stent, % 93.5 91.3 1.0§
Direct stenting, % 60.8 28.3 0.002‡
Number of stents, mean 1.20  0.65 1.13  0.50 0.59§
Stent segment length, mm 18.9  10.5 21.4  12.0 0.31†
Maximum pressure, atm 14.9  3.8 15.2  2.9 0.78†
Stent/vessel ratio 1.00  0.32 1.07  0.18 0.20†
No-reflow, % 2.2 10.8 0.20§
Distal occlusion, % 4.3 15.2 0.08§
Side branch occlusion, % 2.2 2.2 1.0§
GP IIb/IIIa inhibitors, % 43.4 41.3 1.0‡
IABP, % 10.9 10.9 1.0‡
Continuous data presented as mean  SD and were compared by Student t test (*) or Wilcoxon rank-sum test (†); categorical
data are presented as frequency values and were compared by chi-square (‡) or Fisher exact test (§).
DS  diameter stenosis; GP  glycoprotein; IABP  intraaortic balloon pump; IRA  infarct-related artery; MLD 
minimal lumen diameter; RVD  reference vessel diameter; TIMI  Thrombolysis In Myocardial Infarction.
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strategy, the infarct size determined by CK-MB release was
larger in patients with lower postprocedural MBG (267.6
262.5 UI/l in MBG 2 vs. 154.6 139.9 UI/l in MBG-3;
p  0.0001). Stratified by postprocedural MBG, the left
ventricular ejection fraction at both discharge and 30-day
follow-up was higher in MBG-3 than in MBG 2 (53.0 
6.9% vs. 46.0  10.8% and 53.9  7.1% vs. 47.0  8.5%;
p  0.0001). The left ventricular ejection fraction did
significantly improve from baseline to 30-day follow-up in
both groups (thrombectomy: p  0.02; control: p  0.04).
This improvement was not different between treatment
groups (p  0.38). Regardless of treatment strategy in
patients with a final MBG-3, the left ventricular ejection
fraction improved significantly from baseline to 30 days
(50.1 6.6% to 53.9  7.1%; p  0.007), whereas in
patients with MBG 2 this difference was not significant
(47.7  6.8% to 47.0  8.5%; p  0.9).
Figure 2. Thrombolysis In Myocardial Infarction (TIMI) flow grade (A)
and myocardial blush grade (MBG) (B) after each step of the procedure.
There were no differences between groups in TIMI flow at baseline, after
wiring, and at the end of procedure (A). The MBG was similar between
groups at baseline and after wire crossing. At the end of procedure, the
MBG was significantly higher (p  0.006; chi-square) in patients under-
going thrombectomy (B).
Figure 3. Changes in mean myocardial blush grade (MBG) observed
during the procedure. In patients undergoing thrombectomy, the MBG
was enhanced after aspiration (p  0.002; analysis of variance [ANOVA]),
and it did not show further significant improvement (p  0.20; ANOVA)
after optimizing treatment by balloon angioplasty and/or stenting. In
patients undergoing conventional approach, MBG significantly improved
after intervention (p  0.01; ANOVA). At the end of the procedure,
MBG was higher in patients undergoing thrombectomy (p  0.001;
ANOVA). Solid squares  thrombectomy; solid triangles  no throm-
bectomy.
Figure 4. Thrombolysis In Myocardial Infarction (TIMI) flow grade (A)
and myocardial blush grade (MBG) (B) at baseline and after the procedure
according to the use or not of glycoprotein IIb/IIIa inhibitors. There were
no statistically significant differences between groups in TIMI flow and in
MBG (p NS; chi-square).
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Clinical outcomes. The in-hospital occurrence of death,
reinfarction, and severe bleeding were not statistically dif-
ferent between groups (Table 3). In the thrombectomy
group, three patients died during hospitalization, two with
refractory cardiogenic shock, and one because of refractory
ventricular fibrillation. In the control group, three patients
died during hospitalization, two with cardiogenic shock,
and one after massive retroperitoneal bleeding. Reinfarction
occurred in one patient assigned to thrombectomy because
of stent thrombosis, and in one patient assigned to conven-
tional strategy because of non-IRA occlusion. In-hospital
congestive heart failure occurred more often in patients
assigned to conventional strategy, but this difference was not
statistically significant (21.7% vs. 10.9%, p 0.17). Regard-
less of the treatment strategy, patients with postprocedural
MBG 0/1/2 experienced in-hospital heart failure more
frequently than patients with postprocedural MBG-3
(14/42 vs. 1/50, p  0.0001). At 30-day follow-up there
was no difference in major adverse clinical events between
groups (Table 3).
DISCUSSION
Thrombus removal and myocardial reperfusion. The
goal of direct angioplasty for the treatment of AMI is not
only the restoration of normal epicardial flow, but also
achievement of optimal myocardial tissue reperfusion (4).
Myocardial reperfusion can be assessed using angiographic
(8) and electrocardiographic (21,25) parameters.
Thrombus and plaque debris embolization is one of the
mechanisms affecting the microvasculature at the time of
reperfusion by mechanical capillary obstruction leading to
endothelium dysfunction (26), and by inflammation of the
myocardium (27). Using an experimental canine model,
Do¨rge et al. (27) studied the effects of coronary microem-
bolization on the extent of myocardial inflammation and
necrosis showing that the injection of inert microspheres
in the microvascular coronary circulation of the canine
heart led to a similar amount of myocardial necrosis and
systolic dysfunction and a more pronounced inflamma-
tory response compared with an epicardial coronary
occlusion model.
In the present randomized study, patients undergoing
thrombectomy showed similar postprocedure epicardial flow
but improved myocardial reperfusion documented by sig-
nificantly improved myocardial blush and ST-segment res-
olution, compared with patients treated conventionally. It
appears that effective removal of thrombotic material at the
lesion site improves myocardial reperfusion by reducing
distal embolization occurring during plaque manipulation
with balloon and stent.
Further evidence of effective thrombus removal is given
by the significant angiographic reduction in thrombus bur-




(n  46) p Value
In-hospital
Death, % 6.5 6.5 1.0
CHF, % 10.9 21.7 0.17§
Nonfatal reinfarction, % 2.2 2.2 1.0
Stroke, % 0 0 1.0
Severe bleeding, % 2.2 2.2 1.0
TVR, % 0 0 1.0
ST-segment regression, %
50% 82.6 52.2 0.001§
Normalized 58.7 32.6
Regression 50% 100% 23.9 19.6
CK peak, UI/l 1,921.6  1,417.4 2,285.3  1,924.7 0.30†
CK-MB:
peak, UI/l 181.9  154.9 228.6  253.7 0.29†
1–3 times normal, % 28.3 17.4 0.46§
3–8 times normal, % 34.8 41.3
8 times normal, % 36.9 39.1
30 days
Death, % 6.5 6.5 1.0
Reinfarction, % 4.3 4.3 0.2
Stroke 0 0 0
TVR, % 0 0 1.0
LVEF, %
Baseline 49.3  7.6 48.8  5.9 0.5*
At discharge 51.0  7.7 48.7  10.9 0.29*
At 30 days 51.9  7.9 49.9  8.9 0.26*
Continuous data presented as mean  SD and were compared by Student t test (*) or Wilcoxon rank-sum test (†) or ANOVA
(‡); categorical data are (‡) presented as frequency values and were compared by chi-square (§) or Fisher exact test ().
CHF  congestive heart failure; CK  creatine kinase; LVEF  left ventricular ejection fraction; TVR  target vessel
revascularization.
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den after thrombectomy and by the presence of thrombotic
debris in the aspirate in a high percentage of cases.
Myocardial damage and left ventricular function. In
previous studies, myocardial blush has been related to infarct
size, left ventricular function (28), and long-term mortality
after AMI (8,24). In our study, patients treated with
thrombectomy, despite the enhanced myocardial blush, did
not show a significantly smaller myocardial damage assessed
by total CK and CK-MB peak release. We observed a
slight, but not significant, improvement of left ventricular
function and in the occurrence of in-hospital congestive
heart failure. The main explanation for this is probably that
our study was not powered to demonstrate benefits in
myocardial salvage and in ventricular function, but to assess
surrogate markers known to be associated with these.
Interestingly, patients with blush-3, regardless of the mo-
dality of treatment, showed a significant reduction in
myocardial damage and a better ventricular function com-
pared with patients with blush 0/1/2. This underlines the
importance of achieving MBG-3 and supports the validity
of MBG as surrogate end point in AMI studies.
Comparison with other studies. In the present study, the
rate of myocardial blush-3 (71.7%) and ST-resolution
50% (82.6%) after adjunct thrombectomy was high com-
pared with results of conventional balloon angioplasty and
stent reported by van’t Hof and by Stone (8,24) (MBG-3,
19% and 28%, respectively) and Claeys (25) (ST-resolution
50%: 64%). Recently, Beran and colleagues (18) reported
on a randomized trial of thrombectomy versus conventional
treatment including 49 patients with ST-elevation AMI.
They showed a significantly improved ST-resolution but no
difference in myocardial blush and coronary flow reserve
after adjunctive intracoronary thrombectomy with the
X-Sizer catheter. A possible explanation for the lack of
benefit of thrombectomy on myocardial blush and coronary
flow reserve is that in the cited study both parameters were
evaluated in ST- and non-ST-elevation myocardial infarc-
tion. The EndiCor X-SIZER AMI registry (29) showed a
high MBG-3 grade of 62% similar to our findings.
Other mechanical approaches to reduce embolization of
thrombus during direct PTCA have been used successfully.
They include rheolytic thrombectomy (15), thrombus aspi-
ration devices (30), and distal protection devices (31). Data
from randomized studies on the effects of these devices on
myocardial reperfusion during direct PTCA have not been
reported.
Several pharmacologic approaches to improve myocardial
reperfusion during direct angioplasty have been performed.
Intracoronary adenosine and verapamil (32,33) is adminis-
tered to reduce the reperfusion injury but does not address
the reduction of intracoronary thrombus burden. Glyco-
protein IIb/IIIa receptor inhibitors in patients undergoing
direct PTCA has been shown to improve microvascular
function by limiting the effects of embolized thrombus and
platelets, and by reducing the inflammatory response of the
coronary microvasculature, as assessed by coronary flow
velocity (34). Associated therapy of IIb/IIIa inhibitors and
thrombolytic therapy did show a 59% rate of complete
ST-segment resolution (35). In the present study, mechan-
ical thrombectomy aiming to avoid distal embolization
achieved similar good results as aggressive pharmacologic
treatment aiming to reduce the consequences of distal
embolization (32,33). It is unlikely that the results of the
study were affected by the use of glycoprotein IIb/IIIa
inhibitors, as reflected by the similar, relatively low, rate of
abciximab administration in both groups (43.4% in throm-
bectomy arm and 41.3% in conventional arm). In a large
randomized trial (36), the use of abciximab as an adjunct to
direct PTCA did not enhance ST-segment resolution or
improve myocardial recovery at seven months. Also, in the
X-SIZER AMI registry, the use of glycoprotein IIb/IIIa
inhibitors did not show an additional benefit on myocardial
reperfusion in patients treated with thrombectomy (37).
These data underline the importance of mechanical adjuncts
to improve the procedural outcome of direct PTCA.
Study limitations. The study reflects a single-center expe-
rience in a limited number of patients, and represents a
mechanical attempt to optimize myocardial reperfusion in
patients undergoing direct PTCA. Apart from consider-
ations on the safety of the X-Sizer thrombectomy device
and on its effect on myocardial reperfusion, any conclusions
about the clinical efficacy of intracoronary thrombectomy
cannot be drawn.
The study was limited to thrombus-containing lesions in
relatively large coronary arteries and did not include the
entire AMI population. Another limitation of the study is
that the possible treatment benefit of adjunct pharmacologic
therapy was not evaluated. Myocardial reperfusion repre-
sents such a wide and complex scenario, that synergistic
mechanical and pharmacologic strategies to preserve micro-
vascular integrity will be needed.
Conclusions. Intracoronary thrombectomy with the
X-Sizer catheter during catheter-based treatment of AMI
improved myocardial reperfusion as assessed by myocardial
blush and ST-segment resolution. Larger clinical trials are
warranted to address the impact of thrombectomy on infarct
size as well as on clinical outcome.
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